Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05218044 · ClinicalTrials.gov registry record · NA
Cryoablation as a Minimally Invasive Alternative to Surgery for Managing Ductal Carcinoma In Situ
A NA study of Ductal Carcinoma In Situ, sponsored by Glendale Adventist Medical Center d/b/a Adventist Health Glendale.
- Recruiting
- Registry status
- NA
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT05218044: Recruiting NA study of Ductal Carcinoma In Situ, sponsored by Glendale Adventist Medical Center d/b/a Adventist Health Glendale.
NCT05218044 is a NA study of Ductal Carcinoma In Situ that is actively recruiting participants, run by Glendale Adventist Medical Center d/b/a Adventist Health Glendale. The registered enrollment target is 30 participants, below the 255-participant average among 15 other Ductal Carcinoma In Situ trials with a reported enrollment target (88% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05218044, a NA study of Ductal Carcinoma In Situ, is actively recruiting participants, sponsored by Glendale Adventist Medical Center d/b/a Adventist Health Glendale.
- RECRUITING
- Registry status
- NA
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
Cryoablation or tumor freezing is a percutaneous, office-based procedure that is emerging as a minimally invasive, cost-effective alternative to surgery that is currently being evaluated in clinical trials for the management of for early-stage invasive breast cancer. The investigator will also evaluate the potential of cryoablation as a minimally invasive alternative to surgery for small areas of DCIS by examining its ability to achieve complete ablation of DCIS within the targeted cryoablation zone of necrosis.
Primary Outcome
Number of participants to achieve completeness of ablation by measuring the percentage of subjects with no residual DCIS or invasive cancer within the zero of necrosis assessed in the post-cryoablation core biopsy obtained 6 months post-cryoablation.
Conditions Studied
Interventions
- PROCEDURE Cryoablation
Study Locations (1)
California
- Office of Dennis R. Holmes, M.D., F.A.C.S. - Glendale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2021-11-01 |
| Est. Completion | 2026-11-01 |
| Phase | NA |
What NCT05218044 shows while recruiting
NCT05218044 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 255-participant average among 15 other Ductal Carcinoma In Situ trials with a reported enrollment target (88% lower).
The record links to 1 condition, with Ductal Carcinoma In Situ appearing as the primary indexed condition, and to 1 intervention - of which Cryoablation is the first listed.
NCT05218044 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT05218044 about?
NCT05218044 is a clinical study titled "Cryoablation as a Minimally Invasive Alternative to Surgery for Managing Ductal Carcinoma In Situ". Cryoablation or tumor freezing is a percutaneous, office-based procedure that is emerging as a minimally invasive, cost-effective alternative to surgery that is currently being evaluated in clinical trials for the management of for early-stage invasive breast cancer. The investigator will also evalu...
What is the current status of trial NCT05218044?
This trial is currently recruiting. It is a NA study. The enrollment target is 30 participants. The study started on 2021-11-01. Estimated completion is 2026-11-01.
What conditions does trial NCT05218044 study?
This clinical trial studies the following conditions: Ductal Carcinoma In Situ.
What interventions are being tested in trial NCT05218044?
The interventions under investigation include: Cryoablation (PROCEDURE).
Who is sponsoring clinical trial NCT05218044?
This trial is sponsored by Glendale Adventist Medical Center d/b/a Adventist Health Glendale, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05218044 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ductal Carcinoma In Situ
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05218044's enrollment target sits among peer trials
30 14th of 15 higher than 1 of 15 other Ductal Carcinoma In Situ trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Ductal Carcinoma In Situ trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of Disappearing Markers for Daily Radiation Treatment Delivery for Breast Cancer Patients.
RECRUITING · NA
-
Novel Cavity Marking Technique in Breast Cancer Patients Undergoing Breast Conservation Surgery With Oncoplastic Reconstruction for the Delivery of Adjuvant Radiotherapy and Accuracy of Recommended Re-excisions
RECRUITING · NA
-
Comparing an Operation to Monitoring, With or Without Endocrine Therapy (COMET) Trial For Low Risk DCIS
ACTIVE NOT RECRUITING · NA
-
Safety and Efficacy Study of the Xoft® Axxent® eBx® IORT System®
ACTIVE NOT RECRUITING · NA
-
Intraoperative Radiation Therapy (IORT) in DCIS
ACTIVE NOT RECRUITING · NA
-
Living Well After Breast Surgery
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI